Average Co-Inventor Count = 3.42
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Accutar Biotechnology Inc. (20 from 20 patents)
2. Tiger Biotherapeutics Inc. (3 from 3 patents)
23 patents:
1. 12338248 - Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
2. 12331061 - Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
3. 12195459 - Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
4. 12168058 - Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
5. 12110291 - Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
6. 11642342 - Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
7. 11535606 - Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
8. 11530222 - Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders
9. 11521712 - Computational method for classifying and predicting ligand docking conformations
10. 11420956 - Ureas having Androgen Receptor degradation activity and uses thereof
11. 11312702 - Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
12. 11261178 - Chroman derivatives having estrogen receptor degradation activity and uses thereof
13. 11220490 - Ureas having androgen receptor degradation activity and uses thereof
14. 11117885 - Compounds having estrogen receptor alpha degradation activity and uses thereof
15. 10968212 - Compounds having estrogen receptor alpha degradation activity and uses thereof